ALK and non-small cell lung carcinoma: First‐line lorlatinib improved PFS and reduced CNS progression versus crizotinib in patients with advanced ALK + NSCLC with or without BM at baseline. Half of all CNS AEs resolved without intervention or with lorlatinib dose modification.